Loading
Oncolys BioPharma Inc.: what insiders have been doing
This page follows insider dealings at Oncolys BioPharma Inc. as filed with EDINET (Japan FSA). From 18 October 2025 to 18 October 2026, the disclosure feed for Oncolys BioPharma Inc. logged 6 filings by 3 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Over the last twelve months, not one insider purchase of Oncolys BioPharma Inc. stock was filed. Between a trade and the moment it shows up on EDINET (Japan FSA), the median delay is 7 days. The shorter that gap, the sooner other investors can see what insiders have done.
For context, the typical company on the same exchange (median of 3,427 companies) published 3 filings over the same period, against 6 filings here.
Source: insider filings from EDINET (Japan FSA). Past trades are no guide to future returns.
Insider Decl.
31
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 16,162 of 24,148 companies
40.6
score / 100
Value31
Quality51
FCF yld-1.0%
Earn yld-1.0%
EV/EBITDA·
ROE-110%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
JP¥6,830
Analyst consensus
Income statement
RevenueJP¥28.5M
Gross profitJP¥28.5M100% margin
EBITDA-JP¥2B-7176% margin
Net income-JP¥2.1B-7209.6% margin
Valuation
P/Book61.4x
Beta1.06
Balance sheet & cash
Market capJP¥201.1B
Total debtJP¥320M
Free Cash Flow-JP¥1.9B
Debt / Equity25%
Profitability & ownership
ROE-110.1%
ROA-55.4%
% insiders11.1%
% institutions3.9%
Last declaration on 5 February 2026
Declarations31 total
ShareXTKSEDINET:S100XJKK
ShareXTKSEDINET:S100XGRP
100.0% of flowShareXTKSEDINET:S100XG9S
ShareXTKSEDINET:S100XEU1
ShareXTKSEDINET:S100X5UM
11.2% of flowShareXTKSEDINET:S100WWQO
11.3% of flowShareXTKSEDINET:S100WV90
5.4% of flowShareXTKSEDINET:S100WU49
5.9% of flowShareXTKSEDINET:S100WSWC
6.4% of flowShareXTKSEDINET:S100WKD9
7.0% of flowShareXTKSEDINET:S100WK43
7.6% of flowShareXTKSEDINET:S100WHKM
ShareXTKSEDINET:S100SXQ6
ShareXTKSEDINET:S100SL4H
ShareXTKSEDINET:S100SHT0
ShareXTKSEDINET:S100SBWS
2.5% of flowShareXTKSEDINET:S100S56U
2.6% of flowShareXTKSEDINET:S100S39E
25 of 31 declarations
About Oncolys BioPharma Inc.
Oncolis BioPharma Inc. is a Japanese biopharmaceutical company focused on developing innovative cancer treatments. It specializes in the research and commercialization of therapies based on oncolytic viruses.